Thromboprophylaxis
Phase 3Small molecule
Thromboprophylaxis is one of 16 small molecule programs targeting Germ Cell Tumor. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Germ Cell Tumor
#DrugCompanyPhaseTrials
1Antabuse
TevaApproved
Ellence
PfizerApproved
Afinitor
NovartisApproved
Gemzar
Johnson & JohnsonApproved
Iressa
AstraZenecaApproved
Taxol
TevaPhase 3
Blenoxane
Bristol-Myers SquibbPhase 3
Vepesid
AAvyxa
Phase 3
Paraplatin
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Thromboprophylaxis. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMedical University of Vienna